Search Results

You are looking at 1 - 10 of 149 items for :

  • "hematopoietic cell transplant" x
Clear All
Full access

Howard A. Chang, Saro H. Armenian and Thanh H. Dellinger

Hematopoietic cell transplantation (HCT) entails immune dysregulation in both recipients of autologous HCT (auto-HCT) 12 , 13 and allogeneic HCT (allo-HCT). 14 , 15 Allo-HCT recipients in particular are susceptible to graft-versus-host disease (GvHD), a

Full access

Christa Meyer, Lih-Wen Mau, Elizabeth A. Murphy, Ellen M. Denzen, Ellyce Hayes, Darlene Haven, Heather Moore, Jackie Foster, Jaime M. Preussler and Linda J. Burns

Background Hematopoietic cell transplantation (HCT) is an underused therapy for patients with acute myeloid leukemia (AML). 1 Because HCT is performed only at select hospitals in the United States, it is critical to understand physician referral

Full access

Boglarka Gyurkocza and Frederick R. Appelbaum

years or older, treated on several SWOG, ECOG, and MD Anderson Cancer Center protocols between 1976 and 2004, reported a 5-year overall survival rate of 7%. 7 The application of allogeneic hematopoietic cell transplantation (HCT) to patients with AML in

Full access

Potjana Jitawatanarat, Arpita Desai, Pradeep Sharda, Hong Liu, Maureen Ross, Francisco J. Hernandez-llizaliturri, Philip L. McCarthy and George L. Chen

’ institution for further treatment. Cytogenetic evaluation revealed mutation of p53 , del(13q), and del(11q). Because of the high-risk features of his disease, an allogeneic hematopoietic cell transplant (alloHCT) was planned and a donor search initiated. In

Full access

Abraham S. Kanate, Miguel-Angel Perales and Mehdi Hamadani

Allogeneic hematopoietic cell transplantation (allo-HCT) is a standard therapy option for the treatment of advanced hematologic malignancies and select nonmalignant disorders, with >8,000 transplants performed each year in the United States. 1

Full access

Ayman Saad, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Sergio Giralt, Jonathan Gutman, Vincent Ho, Mitchell Horwitz, Joe Hsu, Mark Juckett, Mohamed Kharfan Dabaja, Alison W. Loren, MSCE, Javier Meade, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Julianna Roddy, Gowri Satyanarayana, Mark Schroeder, Carlyn Rose Tan, Dimitrios Tzachanis, Jennifer L. Burns and Lenora A. Pluchino

Overview Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with malignant or nonmalignant hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. 1

Full access

Margaret R. O'Donnell

I recently received a query from the medical director of the National Marrow Donor Program (NMDP) asking what a realistic expectation was for how many patients should be candidates for allogeneic hematopoietic cell transplantation (HCT) each year

Full access

Nicolas C. Issa and Lindsey R. Baden

control measures and the use of antimicrobial prophylaxis, is a key aspect of preventing infections in patients with cancer. In autologous and allogeneic hematopoietic cell transplantation (HCT), declining immunity to vaccine-preventable diseases puts

Full access

Luciano J. Costa and Saad Z. Usmani

hematopoietic cell transplantation (AHCT), and maintenance. 15 The incidence of EMD at diagnosis ranges from 1.7% to 4.5% and from 3.4% to 10% at relapse in different reported series. 17 , 18 EMD must be distinguished from paramedullary extension from bone

Full access

Kim Margolin

Advanced germ cell cancer can be cured in most patients using chemotherapy with or without surgery. A small fraction of patients with nonseminomatous tumors (NSGCT) and an even smaller percentage of seminoma patients are destined to have a less favorable outcome, due to an inadequate response to first-line chemotherapy (failure to achieve remission, finding of residual viable carcinoma at post-chemotherapy surgery, or relapse after achieving a remission). Despite the apparent salvage potential for regimens containing ifosfamide or paclitaxel, no proof exists that such combinations are superior to the standard regimen of four cycles of cisplatin, etoposide, and bleomycin (PEB) in the front-line therapy of patients with advanced NSGCT. Other modifications of first-line therapy, such as the addition of paclitaxel or the use of escalated doses of cisplatin, also have failed to increase the cure rate. The use of single or tandem cycles of high-dose chemotherapy (HDT with autologous hematopoietic cell transplant [aHCT]) in various settings (for selected patients with poor prognostic features before therapy, patients predicted to have a poor outcome based on the rate of serum tumor marker decline while on therapy, and patients in relapse or failure to achieve adequate response to standard therapy) has been evaluated in many phase II and a limited number of phase III trials, which are summarized in this review. Important questions that remain to be answered include the role of new agents and the use of more sophisticated techniques to understand prognostic and predictive factors in selecting therapy for GCT.